Catalent
Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.
| Company type | Public |
|---|---|
Traded as |
|
| Industry | Pharmaceuticals |
| Predecessor | Cardinal Health PTS |
| Founded | 2007 |
| Headquarters | Somerset, New Jersey, U.S. |
Number of locations | 52 (2023) |
Key people | Alessandro Maselli (President, CEO & Director), Matti Masanovich (CFO) |
| Services | Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting |
| Revenue | US$4.26 billion (2023) |
| US$−163 million (2023) | |
Net income | US$−256 million (2023) |
| Total assets | US$10.8 billion (2023) |
| Total equity | US$4.61 billion (2023) |
Number of employees | 17,800 (2023) |
| Website | catalent |
| Footnotes / references Financials as of June 30, 2023. | |
Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc. Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.
In 2014, Catalent became a public company, listed on the New York Stock Exchange.